Home/Pipeline/Undisclosed Asset 2

Undisclosed Asset 2

Infectious Disease

ResearchActive

Key Facts

Indication

Infectious Disease

Phase

Research

Status

Active

Company

Uvax Bio

About Uvax Bio

Uvax Bio is a private, pre-revenue biotech advancing a pipeline of vaccine candidates, with its lead HIV-1 program preparing for a Phase 1 clinical trial sponsored by the NIH. Its core asset is the 1c-SApNP® platform, which utilizes rational antigen design and a multi-layered nanoparticle display to create vaccines with a manufacturing profile akin to proven VLP technologies. The company is backed by Series A funding and over $10M in non-dilutive NIH grants, positioning it to advance high-priority infectious disease programs through early clinical development.

View full company profile

Therapeutic Areas

Infectious Diseases

Other Infectious Disease Drugs

Drug	Company	Phase	Status
Vaccine Platform	Biolingus	Research	Active
Pipeline Antibiotics	BioQ Pharma	Unknown	Active
Antivirals Platform	Qubit Pharmaceuticals	Discovery	Active
Antibiotic Development Program	AF ChemPharm	Pre-clinical	Active
Prophylactic Vaccine Development	ImmuneSpec	Service	Active
Optimized VHH vs. SARS-CoV-2	Ordaos Bio	Pre-clinical	Active
AmorphOX Vaccine	Orexo	Preclinical	Active (with Abera)
Undisclosed Vaccine Program(s)	Brazos Biomedical	Pre-clinical	Active
Undisclosed Asset 1	Uvax Bio	Research	Active
Undisclosed Asset 3	Uvax Bio	Research	Active
Vaccine Immune Response (SARS-CoV-2)	CellChorus	Preclinical	Active
POCKIT™ Central COVID-19 Assay	GeneReach Biotechnology	commercial	Active